OCF-203

OCF-203 is a small molecule inhibitor of Chitinase 1 (Chit1), developed by Ocean Biomedical. It was identified via high-throughput screening as a potent Chit1 inhibitor with anti-fibrotic properties demonstrated in multiple murine models of pulmonary fibrosis. In preclinical studies, OCF-203 showed an 85–90% reduction in collagen accumulation and significant reductions in fibrosis across several animal models, including the bleomycin-induced and Hermansky-Pudlak syndrome (HPS) “pale-ear” mouse models. The drug targets Chitinase 1—a key regulator of tissue damage and remodeling implicated in idiopathic pulmonary fibrosis (IPF), scleroderma-associated interstitial lung disease (SSc-ILD), and other fibrotic diseases—by inhibiting its activity to reduce TGF-β1-stimulated receptor expression and canonical Smad2/3 signaling. Despite promising preclinical results, development has been discontinued before reaching clinical trials[1][2][3][5][7].

Brand names

OCF-203OCF203OCF 203

Other names

Small Molecule XSMX